What is William Blair’s Estimate for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of Neurogene in a research note issued on Tuesday, March 25th. William Blair analyst S. Corwin expects that the company will post earnings of ($1.18) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS and Q4 2026 earnings at ($1.16) EPS.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.05. The company had revenue of $0.93 million for the quarter.

Separately, HC Wainwright decreased their price target on Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $59.80.

Neurogene Price Performance

Shares of NASDAQ NGNE opened at $15.33 on Wednesday. Neurogene has a 1-year low of $13.47 and a 1-year high of $74.49. The business’s 50 day moving average is $16.92 and its two-hundred day moving average is $28.96. The stock has a market capitalization of $227.73 million, a P/E ratio of -3.59 and a beta of 1.01.

Institutional Trading of Neurogene

Institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its position in Neurogene by 18.7% during the fourth quarter. Wellington Management Group LLP now owns 21,717 shares of the company’s stock worth $496,000 after acquiring an additional 3,427 shares during the last quarter. Vestal Point Capital LP purchased a new position in shares of Neurogene in the fourth quarter valued at approximately $1,829,000. Squarepoint Ops LLC grew its holdings in shares of Neurogene by 250.0% in the fourth quarter. Squarepoint Ops LLC now owns 17,431 shares of the company’s stock valued at $398,000 after purchasing an additional 12,451 shares in the last quarter. Two Sigma Investments LP purchased a new stake in Neurogene during the 4th quarter worth approximately $472,000. Finally, RTW Investments LP lifted its holdings in Neurogene by 18.9% during the 4th quarter. RTW Investments LP now owns 1,350,256 shares of the company’s stock worth $30,867,000 after buying an additional 215,000 shares in the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares in the company, valued at approximately $1,225,490.42. This represents a 5.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 9.92% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.